Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BSH 2018 | Personalized dendritic cell vaccine for acute leukemia and multiple myeloma

David Avigan • 16 Apr 2018
BSH 2018
Acute Lymphoblastic Leukemia Acute Myeloid Leukemia Leukemia Multiple Myeloma Vaccines

In this interview, David Avigan, MD, from Beth Israel Deaconess Medical Centre, Boston, MA, discusses the exciting therapeutic area of personalized vaccines, which aim to produce tumor-specific immunity. Prof. Avigan discusses the settings that this has proven most successful in, and highlights promising pre-clinical and clinical trials. This video was recorded at the British Society for Haematology (BSH) 2018 Annual Scientific Meeting, in Liverpool, UK.

More from David Avigan

2:26
Impact of dendritic cell fusion vaccine on the microenvironment and outcomes in multiple myeloma
David Avigan • 26 Aug 2022
1:26
The role of vaccines in AML
David Avigan • 26 Aug 2022
1:10
Immune dysregulation in myeloma and impact on disease progression
David Avigan • 26 Aug 2022
3:31
Vaccines and immunotherapy in hematological malignancies
David Avigan • 8 Sep 2020

Related Videos

4:59
MRD as an endpoint for accelerating drug approval in multiple myeloma: updates from the ODAC meeting
Ola Landgren • 13 Apr 2024
2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals